Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

What is the study about? HER2-RADiCAL is investigating whether some people with HER2 positive breast cancer can safely receive less treatment after surgery. HER2 is a protein which can cause cancer to ...

NICE says that there is some evidence that adding Perjeta to standard adjuvant treatment with Roche’s older HER2 drug Herceptin (trastuzumab) or a biosimilar and chemotherapy reduces the risk of ...

News, November 12, 2014 Alert Pertuzumab ... product targets HER2-positive breast cancer, which accounts for about a quarter of all breast cancers, and works in synergy with trastuzumab.

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with ...